Ivabradine Zentiva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0015 
B.II.a.2.b - Change in the shape or dimensions of the 
13/07/2023 
SmPC and PL 
pharmaceutical form - Gastro-resistant, modified or 
prolonged release pharmaceutical forms and scored 
tablets intended to be divided into equal doses 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
II/0014 
B.I.z - Quality change - Active substance - Other 
20/04/2023 
n/a 
variation 
N/0013 
Minor change in labelling or package leaflet not 
19/08/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0012 
B.II.b.3.a - Change in the manufacturing process of 
31/05/2022 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/02/2022 
24/03/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0010 
B.II.e.1.b.1 - Change in immediate packaging of the 
07/01/2022 
n/a 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
IA/0009 
A.7 - Administrative change - Deletion of 
13/12/2021 
n/a 
manufacturing sites 
R/0008 
Renewal of the marketing authorisation. 
22/07/2021 
29/09/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Ivabradine Zentiva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0007 
B.II.z - Quality change - Finished product - Other 
12/11/2020 
n/a 
variation 
IB/0006/G 
This was an application for a group of variations. 
06/02/2020 
29/01/2021 
Annex II and 
PL 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.d - Change in test procedure for the finished 
Page 4/6 
 
 
 
 
 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.e - Change in test procedure for the finished 
product - Update of the test procedure to comply 
with the updated general monograph in the Ph. Eur. 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
IB/0005/G 
This was an application for a group of variations. 
07/05/2019 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IG/1029 
A.5.b - Administrative change - Change in the name 
18/12/2018 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0003/G 
This was an application for a group of variations. 
15/05/2018 
n/a 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
IB/0002 
B.II.z - Quality change - Finished product - Other 
28/09/2017 
n/a 
variation 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
21/08/2017 
13/08/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
